The Use Of Recombinant Human Erythropoietin (rHuEPO) To Blood Cancer Post-Chemotherapy

Aim:Clinical uses of Recombinant Human Erythropoietin(rHuEPO) effectively increase the level of Hemoglobin in blood and improve quality of life of patients.By the use of recombinant human erythropoietin in post-chemotherapy blood cancer cases such as Lymphoma,chronic lymphocytic leukemia,Multiple myeloma etc,with having relatively lack of erythropoietin,cause improve anemia in these post-chemotherapy blood cancer patients and to provide evidence of effectiveness and safety of rHuEPO.Methods:Blood cancer patients are divided into two groups namely Treatment group(A group) and control group(B group).There is altogether 24 patients in treatment group(male 14 and female 10),to whom rHuEPO is given after chemotherapy for 4 weeks,rHuEPO is given as 150u/kg,subcutaneously,three times a week.20 patients in control group(male 10 and female 10) are not using rHuEPO after chemotherapy.Age:33 to 68 years in both of the group.Primary blood cancers are:Lymphoma(23),Multiple myeloma(9),AML(7),CLL(3),and MDS(2).All of the patients have Hb≤105g/L and/or Hematocrit(Hct)≤0.3 or Hb decreased by≥15g/L after chemotherapy。No patients had received blood transfusion 4 weeks before using EPO.Blood routine check up is done in every week and iron is prescribed after 2 weeks。Result:After 4 weeks of treatment,patients were evaluated for drug effectiveness in both groups。Effectiveness was 54.16%and 20%in treatment and control group respectively,P＜0.05。After 4 weeks of treatment,there was distinct statistical significance.Comparing with pretreatment level, Treatment group has remarkable rise in Hb after 4 weeks(81.29±9.85)对(65.75±12.37), (P＜0.01,whereas control group has not distinct change in Hb level(86.95±11.61)对(84.30±16.25),(P＞0.05.After 4 weeks of treatment,the values of Hb,Hct,and RBC are statistically significant by comparing between two groups。Conclusion:Hemoglobin level is significantly increased after the use of rHuEPO and side effects found lesser with better tolerence.Hence the application of rHuEPO to treat blood cancer (Non-Hodgkin Lymphoma,chronic lymphoid leukemia,multiple myeloma,Myelodysplastic Syndrome,etc) patients with relatively lack of blood erythropoietin in body,in post-chemotherapy stage,is effective and safety to use.。...